Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2096662 Target Snapshot

Serotonin 2 receptors; 5-HT2a & 5-HT2c · SELECTIVITY GROUP · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
723Compounds
66Assays
1Approved Drugs
35.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Serotonin 2 receptors; 5-HT2a & 5-HT2c shows approved-linked disease relevance led by psychosis. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P28223. Start with psychosis, then reuse UniProt P28223 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with psychosis, then reuse UniProt P28223 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
psychosis

Serotonin 2 receptors; 5-HT2a & 5-HT2c shows approved-linked disease relevance led by psychosis. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with psychosis because it currently carries approved-linked support. Linked drugs include SERTINDOLE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serotonin 2 receptors; 5-HT2a & 5-HT2c as ChEMBL target CHEMBL2096662, mapped to UniProt P28223. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serotonin 2 receptors; 5-HT2a & 5-HT2c
SELECTIVITY GROUP · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2096662
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P28223
5-hydroxytryptamine receptor 2A
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Serotonin 2 receptors; 5-HT2a & 5-HT2c is the right protein anchor across sources, using UniProt P28223 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why psychosis is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameSerotonin 2 receptors; 5-HT2a & 5-HT2c
Target TypeSELECTIVITY GROUP
OrganismHomo sapiens
UniProtP28223
ChEMBL ↗ UniProt ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label5-hydroxytryptamine receptor 2A
UniProt AccessionP28223
Component TypeProtein
Sequence Length471 aa

5-hydroxytryptamine receptor 2A

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Serotonin 2 receptors; 5-HT2a & 5-HT2c, mapped to UniProt P28223. ChEMBL maps the protein component as 5-hydroxytryptamine receptor 2A. Sequence length is 471 aa.

Mapped IDP28223
Review nameSerotonin 2 receptors; 5-HT2a & 5-HT2c
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Serotonin 2 receptors; 5-HT2a & 5-HT2c shows approved-linked disease relevance led by psychosis. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
psychosis
1 linked drug · 1 direct · 1 efficacy
Linked drugSERTINDOLE
Late clinical Phase III
anxiety
1 linked drug · 1 direct · 1 efficacy
Linked drugSERTINDOLE
Late clinical Phase III
Cognitive impairment
1 linked drug · 1 direct · 1 efficacy
Linked drugSERTINDOLE
Late clinical Phase III
Dementia
1 linked drug · 1 direct · 1 efficacy
Linked drugSERTINDOLE
Late clinical Phase III
depressive disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugSERTINDOLE
Late clinical Phase III
schizophrenia
1 linked drug · 1 direct · 1 efficacy
Linked drugSERTINDOLE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with psychosis because it currently carries approved-linked support. Linked drugs include SERTINDOLE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasepsychosis
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Approved
Assay Mix

Activity Type Distribution

KI35.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1172812 10.48 Ki 0.033 Preclinical
CHEMBL404232 10.39 Ki 0.041 Preclinical
CHEMBL1173408 10.1 Ki 0.079 Preclinical
CHEMBL1173820 9.96 Ki 0.11 Preclinical
CHEMBL41347 8.22 Ki 6.0 Preclinical
CHEMBL360328 8.12 Ki 7.5 Approved
CHEMBL93850 7.89 Ki 13.0 Preclinical
CHEMBL38911 7.8 Ki 16.0 Preclinical
CHEMBL42463 7.8 Ki 16.0 Preclinical
CHEMBL43916 7.8 Ki 16.0 Preclinical
Distribution

pChEMBL Value Distribution

0
5.0
1
5.5
1
6.0
1
6.5
7
7.0
12
7.5
2
8.0
0
8.5
0
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

LORCASERIN
CHEMBL360328
Approved 2012
Properties Compare Identifier
Assay Landscape

Assay Landscape

66
Total Assays
28
Tested Compounds
3
Assay Types
Binding — 64 assays, 28 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 29 27 7.8
protein format 25 0 —
cell-based format 10 1 8.1
Functional — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0 —
Unassigned — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine